O’Keefe, Joan A. http://orcid.org/0000-0003-4018-7212
Guan, Joseph
Robertson, Erin
Biskis, Alexandras
Joyce, Jessica
Ouyang, Bichun
Liu, Yuanqing
Carnes, Danielle
Purcell, Nicollette
Berry-Kravis, Elizabeth
Hall, Deborah A.
Funding for this research was provided by:
National Institutes of Health (K01 HD088762)
Article History
Accepted: 27 August 2020
First Online: 28 October 2020
Compliance with Ethical Standards
:
: Joan A. O’Keefe receives research support from the NIH (K01 HD088762); she reports no disclosures or conflicts of interests related to this manuscript. Joseph Guan reports no disclosures or conflicts of interests related to this manuscript. Erin Robertson reports no disclosures or conflicts of interests related to this manuscript. Alexandras Biskis reports no disclosures or conflicts of interests related to this manuscript. Jessica Joyce reports no disclosures or conflicts of interests related to this manuscript. Bichun Ouyang no disclosures or conflicts of interests related to this manuscript. Yuanqing Liu reports no disclosures or conflicts of interests related to this manuscript. Danielle Carnes reports no disclosures or conflicts of interests related to this manuscript. Nicollette Purcell reports no disclosures or conflicts of interests related to this manuscript. EBK has received funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin, Ovid, Acadia, Yamo, Ionis, Ultragenyx, Lumos, GeneTx Pharmaceuticals to consult on trial design or development strategies and/or conduct clinical trials in FXS or other NDDs or neurodegenerative disorders, from Vtesse/Sucampo/Mallinkcrodt to conduct clinical trials in NP-C, and from Asuragen Inc. to develop testing standards for <i>FMR1</i> testing as well as research support from NICHD, NINDS, NIMH, CDC, NCATS and the John Merck Fund. All funding to EBK is directed to Rush University Medical Center to support rare disease programs. EBK receives no personal funds. She reports no conflicts of interests related to this manuscript. Deborah A. Hall receives research support from the NIH, the Parkinson’s Foundation, Abbvie, Biogen, Biohaven, Neurocrine, Fujifilm, and Pfizer; she reports no conflicts of interests related to this manuscript.